# NCT06110663 (NCT06110663)

> A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06110663
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Conditions: Non-Small Cell Lung Cancer
- Interventions: HS-10241+ Almonertinib; Pemetrexed + Cisplatin /Carboplatin
- Enrollment: 314
- Primary outcome: Progression-free Survival (PFS) evaluated by Independent Review Committee (IRC)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06110663